Neoprenewel (Indapamide, Perindopril Arginine)

Indapamide promotes the excretion of sodium and water by inhibiting reabsorption in the distal tubule, reducing plasma volume. Perindopril arginine blocks the angiotensin‑converting enzyme, preventing formation of angiotensin II, which leads to vasodilation and decreased aldosterone‑mediated fluid retention. Together they lower vascular resistance and blood pressure.

The specific dose of Neoprenewel is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any concomitant medications. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for Neoprenewel in pregnancy and lactation are limited. ACE inhibitors are generally avoided during the second and third trimesters because of fetal toxicity, and the diuretic component may affect fluid balance. Use only if the potential benefit justifies the risk and after consulting a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Neoprenewel combines a thiazide‑like diuretic and an ACE inhibitor, offering a dual mechanism that can provide superior blood‑pressure reduction compared with monotherapy. Compared with separate tablets, the fixed‑dose combination may improve adherence, but clinicians must consider individual patient tolerance and potential drug‑interaction profiles.

Neoprenewel should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Neoprenewel is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Serious risks include angioedema, severe hypotension, acute renal impairment, and hyperkalemia. Patients should be educated to seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, marked decrease in urine output, or muscle weakness.

Neoprenueil is contraindicated in patients with known hypersensitivity to indapamide, perindopril, or any ACE‑inhibitor component, as well as those with a history of angioedema related to ACE inhibitors. It should also be avoided in individuals with severe renal artery stenosis or those taking aliskiren concomitantly.